Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 17/20 | 0.70 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.55 |
| ▸ | CCR3 | P51677 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4040184 | 0.84 | SIGMAR1 (0.74) | SIGMAR1MCHR1 | |
| SCHEMBL4202919 | 0.84 | SIGMAR1 (0.70) | SIGMAR1MCHR1CCR3ALDH1A1 | |
| SCHEMBL8023864 | 0.82 | SIGMAR1 (1.00) | SIGMAR1CCR3 | |
| SCHEMBL6333442 | 0.82 | SIGMAR1 (0.73) | SIGMAR1 | |
| SCHEMBL6330819 | 0.79 | SIGMAR1 (0.44) | SIGMAR1ALDH1A1 | |
| SCHEMBL17950892 | 0.77 | SIGMAR1 (0.60) | SIGMAR1MCHR1CCR3 | |
| SCHEMBL4034703 | 0.76 | SIGMAR1 (0.62) | SIGMAR1MCHR1CCR3ALDH1A1 | |
| SCHEMBL6327856 | 0.75 | SIGMAR1 (0.71) | SIGMAR1MCHR1CCR3ALDH1A1 | |
| SCHEMBL17950911 | 0.75 | SIGMAR1 (0.60) | SIGMAR1MCHR1CCR3ALDH1A1 | |
| SCHEMBL19493171 | 0.74 | SIGMAR1 (0.57) | SIGMAR1MCHR1CCR3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6958350-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2005-10-25 | — | — | US | disclosed |
| EP-1363902-B1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2004-09-15 | — | — | EP | disclosed |
| US-20040102483-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2004-05-27 | — | — | US | disclosed |
| EP-1363902-A1 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2003-11-26 | — | — | EP | disclosed |
| WO-2002066460-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2002-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102483-A1 | Chemical compounds | CXCR1, CXCR2, CXCR4 | SIGMAR1 269/4885MCHR1 211/4885CCR3 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.